C Goddard
Impact in
- Genetics top 5%
- Glioma Diagnosis and Treatment
- Physiology top 10%
Papers in
-
- Cancer therapeutics and mechanisms 2
- Biochemical and Molecular Research 2
- Metabolism, Diabetes, and Cancer 1
-
- Synthesis and biological activity 3
- Synthesis and Characterization of Heterocyclic Compounds 3
- Co-authors
- Marianna M. Newkirk (1 shared paper)Richard Kahn (1 shared paper)J A Slack (4 shared papers)M. F. G. STEVENS (3 shared papers)Ronald L. Felsted (4 shared papers)J A Hickman (1 shared paper)Neil W. Gibson (1 shared paper)R. L. Stone (1 shared paper)
- Journals
- The Analyst (2 papers)Journal of Biological Chemistry (2 papers)Biochemical Journal (2 papers)SLAS DISCOVERY (1 paper)British Journal of Cancer (1 paper)
- Partner nations
- United StatesUnited KingdomMalaysia
In The Last Decade
C Goddard
17 papers receiving 811 citations
Hit Papers
Peers
Comparison fields: 5 of 99
- Genetics 184
- Physiology 38
- Cell Biology 123
- Oncology 195
- Molecular Biology 480
Countries citing papers authored by C Goddard
This map shows the geographic impact of C Goddard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Goddard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Goddard more than expected).
Fields of papers citing papers by C Goddard
This network shows the impact of papers produced by C Goddard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Goddard. The network helps show where C Goddard may publish in the future.
Co-authors
The 25 scholars most cited alongside C Goddard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Hit paper breakdown → | 1987 | 335 |
| 2 | 1988 | 144 | |
| 3 | 1990 | 89 | |
| 4 | 1988 | 57 | |
| 5 | Phase I clinical trial of mitozolomide. | 1985 | 39 |
| 6 | 1994 | 36 | |
| 7 | 1989 | 32 | |
| 8 | 1995 | 28 | |
| 9 | 1994 | 24 | |
| 10 | 1996 | 14 | |
| 11 | 1985 | 12 | |
| 12 | 1989 | 10 | |
| 13 | 1986 | 10 | |
| 14 | 1988 | 9 | |
| 15 | 1994 | 3 | |
| 16 | 1985 | 3 | |
| 17 | 1994 | 1 |
About C Goddard
C Goddard is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Immunology and Pharmacology, having authored 17 papers that have together received 846 indexed citations. Recurring topics across this work include Synthesis and biological activity (3 papers), Synthesis and Characterization of Heterocyclic Compounds (3 papers), Cancer therapeutics and mechanisms (2 papers), Fungal Plant Pathogen Control (2 papers), Biochemical and Molecular Research (2 papers), Acoustic Wave Resonator Technologies (1 paper), HIV Research and Treatment (1 paper) and Metabolism, Diabetes, and Cancer (1 paper). The work is most often cited by research in Genetics (184 citations), Physiology (38 citations), Cell Biology (123 citations), Oncology (195 citations) and Molecular Biology (480 citations). C Goddard has collaborated with scholars based in United States, United Kingdom and Malaysia. Frequent co-authors include Marianna M. Newkirk, Richard Kahn, J A Slack, M. F. G. STEVENS, Ronald L. Felsted, J A Hickman, Neil W. Gibson, R. L. Stone, Daniel Chubb and Constance J. Glover. Their work appears in journals such as The Analyst, Journal of Biological Chemistry, Biochemical Journal, SLAS DISCOVERY and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.